Literature DB >> 9882036

Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection.

W D Chey1, L Fisher, J Barnett, J Delvalle, G H Elta, W L Hasler, T Nostrant, J Palaniappan, J Scheiman.   

Abstract

BACKGROUND: We report a clinical trial which evaluated the effectiveness of triple therapy containing low- and high-dose azithromycin to treat Helicobacter pylori infection.
METHODS: From March 1997 to March 1998, patients infected with H. pylori were assigned to receive either: Treatment 1: ranitidine bismuth citrate (RBC) (400 mg b.d.) and amoxycillin (1 g b.d.) for 10 days with azithromycin 500 mg o.m. for 3 days: or Treatment 2: RBC and amoxycillin for 10 days with azithromycin 1 g o.m. for 3 days. H. pylori eradication was established by a urea breath test at least 4 weeks after therapy. Side-effects and compliance were assessed using a diary.
RESULTS: Sixty-eight patients were enrolled. Fifty-seven per cent of patients were treated for active peptic ulcer disease or a history of peptic ulcer disease. Treatment 1 cured H. pylori in 44% and 44% by per protocol and intention-to-treat analysis, respectively. The corresponding eradication rates for Treatment 2 were 79% and 75%. Two patients taking Treatment 2 dropped out of the study because of side-effects.
CONCLUSIONS: With RBC and amoxycillin for 10 days, azithromycin at a dose of 1 g/day for 3 days was significantly better at curing H. pylori infection than azithromycin 500 mg/day for 3 days.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9882036     DOI: 10.1046/j.1365-2036.1998.00422.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Helicobacter Pylori.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

2.  Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis.

Authors:  Jie Dong; Xiao-Feng Yu; Jian Zou
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

3.  Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer.

Authors:  Vladimir T Ivashkin; Tatiana L Lapina; Oksana Yu Bondarenko; Olga A Sklanskaya; Petr Ya Grigoriev; Yuri V Vasiliev; Emilia P Yakovenko; Pavel V Gulyaev; Valeri I Fedchenko
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

4.  Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.

Authors:  Mohammad Hassan Emami; Mohammad Mehdi Saberfiroozi; Abbas Arj; Ali Reza Taghavi; Kamran Bagheri-Lankarani; Najaf Dehbashi; Mohammad Reza Fattahi; Mahvash Alizadeh; Mohammad Javad Kaviani; Rahim Bahri-Najafi; Bita Geramizadeh; Abbas Esmaeili
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

5.  Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for Helicobacter pylori eradication in dyspepsia.

Authors:  Shahram Agah; Babak Shazad; Babak Abbaszadeh
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

6.  Short-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy.

Authors:  Fernando M Silva; Jaime N Eisig; Ana Cristina S Teixeira; Ricardo C Barbuti; Tomás Navarro-Rodriguez; Rejane Mattar
Journal:  BMC Gastroenterol       Date:  2008-05-29       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.